[{"uuid": "343d9319-d401-3515-ab95-ca97bc5b121a", "title": "Shareholders in CytomX Therapeutics (NASDAQ:CTMX) are in the red if they invested five years ago", "publisher": "Simply Wall St.", "link": "https://finance.yahoo.com/news/shareholders-cytomx-therapeutics-nasdaq-ctmx-142115313.html", "providerPublishTime": 1738160475, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b", "width": 1194, "height": 432, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/eZ0FiSKCVDYnTK6X1bRieQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CTMX"]}, {"uuid": "2d28728f-cfa0-3d65-9c7c-c9f90f5f24f0", "title": "PFE Stock Rises on Reports of Averting Proxy Fight With Activist Investor", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/pfe-stock-rises-reports-averting-152200714.html", "providerPublishTime": 1738077720, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/IW5EhxEFuSd4V4nUFOhT_A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1e2f63f10f05b0390ba8b63bd4ef031c", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/AxvgHTECT_FnPZu0GsWG_A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/1e2f63f10f05b0390ba8b63bd4ef031c", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["PFE", "CSTL"]}, {"uuid": "cb240420-1aab-3f62-8acc-2fe4c7579dc7", "title": "CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/cytk-stock-rises-enrollment-begins-161900028.html", "providerPublishTime": 1737649140, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/46gFT4Y7HZuuo2Xj6ImXmw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/35df2d293bff824e6b9f2134b8f740a3", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/VuDbIK23jerGm8ofHmy3sQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/35df2d293bff824e6b9f2134b8f740a3", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CYTK"]}, {"uuid": "2beebf42-d0d2-34ca-9c64-03e39a3842e3", "title": "Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/keros-therapeutics-stock-plunges-81-141300812.html", "providerPublishTime": 1737641580, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/Z2Y2lgbJQfUa74IVYcsxPA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/41b7bdd28f63138df08f17b665d3589a", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/U5YlhffUr8O4Y.ygF6AjOw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/41b7bdd28f63138df08f17b665d3589a", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["KROS"]}, {"uuid": "cc35b8f7-676c-375f-8489-c02d69f00f7c", "title": "AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/astrazeneca-secures-fda-nod-adc-190500987.html", "providerPublishTime": 1737399900, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/6pmiwRZRhtc7hxDNA3zxVQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ef77d5a5eb4e72e4dd31ccfaf4ca4ccd", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/8ePNUSx6ARln9LO4PZCjpQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/ef77d5a5eb4e72e4dd31ccfaf4ca4ccd", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AZN", "CTMX"]}, {"uuid": "126f6cbe-db7f-37a6-abd0-d55b1e39c799", "title": "Amgen's Lumakras Gets FDA Nod for Expanded Use in Colorectal Cancer", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/amgens-lumakras-gets-fda-nod-141800343.html", "providerPublishTime": 1737382680, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/KEj1lCkxRqndrrMrF3m.HA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c7450ec9df154559fbeb393640d6629", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/L9oXp_PBujUXs0r0RIkKrg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/9c7450ec9df154559fbeb393640d6629", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AMGN"]}, {"uuid": "cc329621-f21f-3696-878a-80e32beaf126", "title": "Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/good-idea-invest-stoke-therapeutics-152800824.html", "providerPublishTime": 1737127680, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/sb.6qRd7FfGt7.wCjWz2vw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/y6B.X5ymHvNNdOly.Nnp7w--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["STOK"]}, {"uuid": "389f7e6a-306f-32de-b2bc-1cebe302c4d0", "title": "IBRX Stock Soars on Completing Filing for Cancer Therapy in EU & UK", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/ibrx-stock-soars-completing-filing-143500735.html", "providerPublishTime": 1737124500, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/sb.6qRd7FfGt7.wCjWz2vw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/y6B.X5ymHvNNdOly.Nnp7w--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2", "width": 140, "height": 140, "tag": "140x140"}]}}, {"uuid": "010f2ab7-1430-3e83-9990-46a9701e0f71", "title": "ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer Candidate", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/atra-stock-down-fda-issues-142400167.html", "providerPublishTime": 1737123840, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/W_dXstIrgNfujttWWGqEAw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ATRA"]}, {"uuid": "3a6ce9ea-e829-3a2b-83a3-d56500da2b7a", "title": "MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/mirm-shares-rise-12-week-170900763.html", "providerPublishTime": 1737047340, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/.WQmSb1MJO1_eLnmBVS1zA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/pa5q6Axi5bBp9pCuwXBcUg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["MIRM"]}, {"uuid": "1effedb7-4e1f-3694-b7aa-84a0d5194194", "title": "InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/inflarx-stock-rises-8-conditional-154900009.html", "providerPublishTime": 1737042540, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/UtFJmA2Sogt3ia9UtBrVtA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/90c6165961c32b679207868449ac44ae", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/W7_U.zwAlTUJvDO9hN5kQQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/90c6165961c32b679207868449ac44ae", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["IFRX"]}, {"uuid": "1e225cce-8728-32f1-a7d1-3b8af78ea7e4", "title": "ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals (Revised)", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/acad-seeks-eu-nod-rett-142800627.html", "providerPublishTime": 1737037680, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/.WQmSb1MJO1_eLnmBVS1zA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/pa5q6Axi5bBp9pCuwXBcUg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307", "width": 140, "height": 140, "tag": "140x140"}]}}]